Treating alcohol withdrawal with oral baclofen: A randomized, double‐blind, placebo‐controlled trial
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Abrupt cessation of alcohol intake causes habituated drinkers to experience symptoms of alcohol withdrawal syndrome (AWS). OBJECTIVE: To determine the effect of the gamma‐aminobutyric acid (GABA)‐B agonist baclofen on the course of acute symptomatic AWS. DESIGN: Prospective, randomized, double‐blind, placebo‐controlled clinical study. SETTING: Two tertiary‐care hospitals in Duluth, Minnesota. PATIENTS: Inpatient adults admitted for any reason (including AWS) judged to be at high risk for AWS. INTERVENTION: Inpatients who developed symptoms of AWS received symptom‐triggered benzodiazepine treatment using lorazepam by standard protocol, and were randomized to receive baclofen 10 mg or placebo, 3 times per day, orally. MEASUREMENTS: AWS severity was assessed using the Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA‐Ar); lorazepam dose was monitored. RESULTS: Seventy‐nine subjects were enrolled. The 44 subjects who developed symptoms of AWS were randomized to baclofen or placebo. Thirty‐one subjects (18 baclofen, 13 placebo) completed 72 hours of assessments, either entirely as inpatients or with outpatient follow‐up. The need for high doses of benzodiazepines (20 mg or more of lorazepam over 72 hours) to control AWS was less likely in the baclofen treatment group (1 of 18) than in the placebo‐treated group (7 of 13) (P = 0.004). CONCLUSIONS: We found that the use of baclofen was associated with a significant reduction in the use of high doses of benzodiazepine (lorazepam) in the management of symptomatic AWS. The use of low‐dose baclofen in the management of AWS deserves further study, as reduced dependence on high‐dose benzodiazepines in AWS management could improve patient safety. Journal of Hospital Medicine 2011;6:474–479. © 2011 Society of Hospital Medicine
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saitz, R. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp042262 · Cited by 599
Baclofen in the Treatment of Alcohol Withdrawal Syndrome: A Comparative Study vs Diazepam
Addolorato, G., Leggio, L., Abenavoli, L., Agabio, R., Caputo, F., Capristo, E., Colombo, G., Gessa, G. L., & Gasbarrini, G. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.08.042 · Cited by 203
Cited by
The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective
de Beaurepaire, R., Sinclair, J. M. A., Heydtmann, M., Addolorato, G., Aubin, H.-J., Beraha, E. M., Caputo, F., Chick, J. D., de La Selle, P., Franchitto, N., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00708 · Cited by 95
Pharmacological approaches to reducing craving in patients with alcohol use disorders
Haass-Koffler, C. L., Leggio, L., & Kenna, G. A. (2014) · CNS Drugs · doi:10.1007/s40263-014-0149-3 · Cited by 83
“On the basis of its limited liver metabolism, baclofen was hypothesized as a pharmacotherapy intervention suitable for alcoholic patients with cirrhosis [186], including those with hepatitis C virus infection [187], and effective in suppressing alcohol withdrawal [183, 185, 188].”
Garbutt, J. C., Kampov-Polevoy, A. B., Pedersen, C., Stansbury, M., Jordan, R., Willing, L., & Gallop, R. J. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01055-w · Cited by 68
Baclofen for alcohol withdrawal
Liu, J., & Wang, L.-N. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008502.pub4 · Cited by 26
Baclofen and the Alcohol Withdrawal Syndrome—A Short Review
Cooney, G., Heydtmann, M., & Smith, I. D. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00773 · Cited by 24
Crunelle, C. L., Jegham, S., Vanderbruggen, N., & Matthys, F. (2023) · Alcohol and Alcoholism · doi:10.1093/alcalc/agad050 · Cited by 5
Metadata
- Authors
- Lyon, J. E., Khan, R. A., Gessert, C. E., Larson, P. M., & Renier, C. M.
- Venue
- Journal of Hospital Medicine
- Publisher
- Wiley
- Published
- 2011-10
- Volume
- 6
- Issue
- 8
- Pages
- 469-474
- ISSN
- 1553-5592 (ISSN-L)
- 1553-5606
- OpenAlex
- W2040779673
- Cited by
- 60
- References
- 2
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.